Breakthrough Studies
Stay updated on groundbreaking scientific research and medical discoveries. This section highlights significant studies shaping the future of healthcare and treatment.
Mersana stock falls after cancer drug data (MRSN:NASDAQ) | Seeking Alpha
Mersana Therapeutics (MRSN) stock hits a 52-week low in reaction to early clinical results for its cancer drug Emi-Le in solid tumors.
Nanoparticle immune therapy shows potential to halt pancreatic cancer spread
Pancreatic cancer remains one of the most challenging tumors to treat, partly because it is often discovered at advanced stages when the disease has already spread, or metastasized. About half of pancreatic cancer patients experience metastasis to the liver, which worsens the prognosis for an already life-threatening disease.
CDC report adds to evidence that HPV vaccine is preventing cervical cancer in US women
A new government report adds to evidence that the HPV vaccine, once called dangerous by Health and Human Services Secretary Robert F. Kennedy Jr., is preventing cervical cancer in young women.
Experimental vaccine for common cancer shows potential in clinical trial
At Memorial Sloan Kettering Cancer Center (MSK) in New York, an experimental approach to treating the cancer with a messenger RNA (mRNA)-based therapeutic vaccine “continues to show potential” in reducing the risk of the disease returning after surgery, according to a press release.
New technique to measure circulating tumor DNA in metastatic cancer may improve surveillance and outcomes
In metastatic cancer surveillance, monitoring the actual concentrations of circulating tumor DNA (ctDNA) may be critical. Researchers showed that absolute ctDNA concentration thresholds can be defined to rule out or predict impending cancer progression.
Telix kidney cancer imaging agent granted FDA priority review
Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for its breakthrough investigational kidney cancer PET[1] imaging agent TLX250-CDx (Zircaix¨[2], 89Zr-DFO-girentuximab), granted a Priority Review and provided a PDUFA[3] date of 27 August 2025, paving the way for a U.S. commercial launch in 2025.
AI-driven blood analysis may spur cancer detection, Hong Kong prenatal test pioneer says
Affordable cancer screening may be available to Hong Kong residents within three years, as advances in artificial intelligence (AI) make the early detection of malignant tumours easier and faster, according to the creator of a pioneering prenatal test for Down syndrome.
Revolutionary Biology Discovery Combines DNA and RNA to Fight Cancer
Scientists have discovered a new way to fight cancer by combining DNA and RNA, leading to a revolutionary biology discovery.
Immune response that may stop breast cancer from spreading identified
A new Moffitt Cancer Center study has identified a specific immune response that may prevent the spread of breast cancer cells within the body.
Light-activated dyes show promise in targeting cancer cells
Melanoma is one of the most aggressive skin cancers, with more than 300,000 new cases reported worldwide each year. In Europe, the number of diagnoses has been rising rapidly.
Urinary DNA methylation test shows some promise for noninvasive bladder cancer screening
Researchers led by the University of Ulsan College of Medicine, Korea, have checked the performance of a noninvasive urinary DNA methylation test for bladder cancer diagnosis.
Common chemical in everyday products may raise your liver cancer risk
Scientists from the University of Southern California have found that exposure to a widely used synthetic chemical is linked to a higher risk of developing liver cancer. The chemical, called perfluorooctane sulfate (PFOS), belongs to a group of man-made substances known as per- and polyfluoroalkyl substances (PFAS).
